Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 19, 2018ACS Medicinal Chemistry LettersOpen Access

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

View Full Paper
Ask AI
Bookmark
Share

Authors

JPJaneta Popovici-MüllerAcorda Therapeutics (United States)RLRené M. LemieuxAcorda Therapeutics (United States)EAErin ArtinGoethe University Frankfurt

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Popovici-Müller et al. (2018) studied this question.

synapsesocial.com/papers/69de6e29210a0977fce9429bhttps://doi.org/10.1021/acsmedchemlett.7b00421
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1ACTR-46. AG-120, A FIRST-IN-class MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: UPDATED RESULTS FROM THE PHASE 1 NON-ENHANCING GLIOMA POPULATION2017 · 34 citations
  2. 2Pharmacokinetic/pharmacodynamic (PK/PD) profile of AG-120 in patients with IDH1-mutant cholangiocarcinoma from a phase 1 study of advanced solid tumors.2017 · 3 citations
  3. 3Attenuating pregnane X receptor (PXR) activation: A molecular modelling approach2006 · 81 citations
  4. 4Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts.2017 · 97 citations
  5. 5An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells2013 · 1,177 citations